Sunshine Biopharma Inc.'s wholly owned Canadian subsidiary, Nora Pharma Inc., has introduced Gabapentin, a new generic anticonvulsant medication, to the Canadian market. This launch signifies a strategic move to expand their presence in Canada's thriving $9.4 billion generic drugs market. Gabapentin, a generic version of Neurontin®, is utilized for treating neuropathic pain and epilepsy, as well as conditions like diabetic neuropathy, central pain, and postherpetic neuralgia. Nora Pharma's Gabapentin is available in capsule form in strengths of 100 mg, 300 mg, and 400 mg, catering to both children and the elderly due to ease of administration. This initiative aligns with the broader growth of the global Gabapentin market, projected to reach $3.07 billion by 2030, driven by factors such as the increasing prevalence of neurological disorders and a shift away from opioid use for pain management.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.